Tysabri Returns, But Biogen Idec’s Oral MS Drug Buy May Mean More
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Of the two recent events with major implications for Biogen Idec’s multiple sclerosis franchise, the less prominent – the acquisition of Fumapharm, its partner on the experimental oral MS therapeutic BG-12 – could, in the long run, be more significant than the re-approval of Tysabri.
You may also be interested in...
Genentech Enters Type 1 Diabetes Space In Licensing Deal With Bayhill
Transaction offers an example of how Genentech and Roche’s business development arms will operate post-merger.
Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.
Biogen Idec Oral MS Agent BG-12 Safety Takes Center Stage At Firm’s R&D Day
Biogen Idec highlighted the safety profile of its oral multiple sclerosis compound BG-12 during its recent R&D Day.